抗凝血酶-Ⅲ测定对肝癌TAE后肝功能的估价  

Significance of AT--III Activity in The Evaluation of Hepatic Carcinoma After TAE Therapy

作　　者：王天才[1] 杨玉珍[1] 王思元[1] 梁扩寰[1] 

机构地区：[1]同济医科大学同济医院内科

出　　处：《临床肝胆病杂志》1993年第4期216-218,共3页Journal of Clinical Hepatology

摘　　要：本文对130例肝病患者(其中肝癌50例)进行了AT-Ⅲ活性测定,有76例AT-Ⅲ活性(57.2±34.5%)低于正常范围(<70%)。正常人AT-Ⅲ活性平均值为100.0±26.7%。90%肝癌患者施行TAE治疗后AT-Ⅲ活性明显降低(38.2±30.2%)。AT-Ⅲ是一种较敏感的肝功能指标,且肝癌施行TAE治疗前、后AT-Ⅲ测定均较PT测定为敏感(栓前p<0.05,栓后p<0.001)、亦优于其它常规肝功能指标。TAE治疗后AT-Ⅲ活性明显降低者预后不佳,不宜重复施行TAE治疗。AT--Ⅲ activity was decreased in 130 cases of liver diseases (included50 cases of hepatic carcinoma). AT--Ⅲ activity was below normal range(<70%) in 76 cases out of 130 patients (57.2±34. 5%), While that of nor-mal controls was 100.0±26.7%. AT--Ⅲ activity was significantly decreas-ed (34.8±30.2%) in 90% cases of hepatic carcinoma (45/50 cases) afterTranscatheter arterial embolization. AT--Ⅲ activity is a sensitive indexof reflecting liver function and better than prothrombin time (before TAEtherapy P<0. 05, after TAE therapy p<0.001) and other commen liverfunction test. The decrease of AT--Ⅲ therapy predict a poor prognosis.In these cases, the repeated TAE therapy is not recommended.

关 键 词：导管动脉栓塞 抗凝血酶Ⅲ 肝肿瘤 

分 类 号：R735.705[医药卫生—肿瘤]